NFKB1 and neoplasm: CDDO-Me targets nuclear factor erythroid-2 related factor-2, JAK/STAT, NF-kB, etc. Treatment of tumor cells with CDDO-Me attenuates tumor growth and inhibits the Wnt/β-catenin pathway.